|Skubitz KM, Campbell KD, Ahmed K, et al. CD66 family members are associated with tyrosine kinase activity in human neutrophils. J Immunol 1995; 155:5382-5390. |
Skubitz KM, Campbell KD, Skubitz APN. Cd66a, CD66b, CD66c, and CD66d each independently stimulate neutrophils. J Leuk Biol 1996; 60:106-117.
Skubitz KM, Campbell KD, Iida J, Skubitz APN. CD63 associates with tyrosine kinase activity and CD11/CD18, and transmits an activation signal in neutrophils. J. Immunol 1996;157: 3617-3626.
Skubitz KM. A phase I study of ambulatory continuous infusion Paclitaxel. Anti-Cancer Drugs 1997; 8:823-828.
Skubitz KM, Skubitz APN. Mechanism of transient dyspnea induced by pegylated-liposomal doxorubicin (Doxil™). Anti Cancer Drugs 1998; 9:45-50.
Anderson PM, Schroeder G, Skubitz KM. Oral glutamine reduces duration and severity of stomatitis after cytotoxic cancer chemotherapy. Cancer 1998; 83:1433-1439.
Skubitz KM, Campbell KD, Skubitz, APN. CD63 associates with CD11/CD18 in large detergent-resistant complexes after translocation to the cell surface in human neutrophils. FEBS Lett 2000; 469: 52-62.
Skubitz KM, Campbell KD, Skubitz APN. Synthetic peptides of CD66a neutrophil adhesion to endothelial cells. J Immunol 2000; 164:4257-4264.
Skubitz KM, Anderson PM. Inhalational IL-2 liposomes for pulmonary metastases: A phase I clinical trial. Anti-Cancer Drugs 2000; 11:555-563.
Skubitz KM, Campbell KD, Skubitz APN. Synthetic peptides from the N-domains of CEACAMs activate neutrophils. J Peptide Res 2001; 58:5-5-526.
Skubitz KM. Phase II trial of pegylated liposomal doxorubicin in mesothelioma. Cancer Invest 2002; 20:693-699.
Skubitz KM, Skubitz APN. Differential gene expression in renal cell carcinoma. J Lab Clin Med 2002; 140:52-64.
Cho JY, Skubitz KM, Katz DR, Chain BM. CD98-dependent homotypic aggregation is associated with translocation of protein kinase C delta and activation of mitogen-activated protein kinases. Exp Cell Res 2003; 286:1-11.
Skubitz KM. Phase II trial of pegylated-liposomal doxorubicin (Doxil) in sarcoma. Cancer Invest 2003; 21:167-176.
Skubitz KM, Skubitz AP. Differential gene expression in uterine leiomyoma. J Lab Clin Med 2003; 141:297-308.
Vallera DA, Elson M, Brechbiel MW, Dusenbery KE, Burns LJ, Skubitz KM, Jaszcz WB, Ramsay NK, Panoskaltsis-Mortari A, Kuroki DW, Wagner JE, Kersey JH. Preclinical studies targeting normal and leukemic hematopoietic cells with Yttrium-90-labeld anti-CD45 antibody in vitro and in vivo in nude mice. Cancer Biother Radiopharm 2003; 18:133-145.
Skubitz KM, Skubitz AP. Differential gene expression in leiomyosarcoma. Cancer 2003; 98:1029-1038.
Skubitz KM, Skubitz AP. Gene expression in aggressive fibromatosis. J Lab Clin Med 2004; 143: 89-98.
Burleson KM, Casey RC, Skubitz KM, Pambuccian SE, Oegema TR Jr, Skubitz AP. Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers. Gynecol Oncol 2004; 93:170-181.
Skubitz KM, Skubitz AP. Role of gene expression arrays in sarcomas. Curr Oncol Rep 2004; 6:309-314.
Hibbs K, Skubitz KM, Pambuccian SE, Casey RC, Burleson KM, Oegema TR Jr, Thiele JJ, Grindle SM, Bliss RL, Skubitz AP. Differential gene expression in ovarian carcinoma: Identification of potential biomarkers. Am J Pathol 2004; 165:397-414.
Skubitz KM, Skubitz AP. Characterization of sarcomas by means of gene expression. J Lab Clin Med 2004; 144:78-91.
Skubitz KM, Cheng EY, Clohisy DR, Thompson RC, Skubitz AP. Gene expression in giant-cell tumors. J Lab Clin Med 2004; 144:193-200.
Skubitz KM, Cheng EY, Clohisy DR, Thompson RC, Skubitz AP. Differential gene expression in liposarcoma, lipoma, and adipose tissue. Cancer Invest. 23:105-118, 2005.
Stroncek DF, Shankar RA, Skubitz KM. The subcellular distribution of myeloid-related protein 8 (MRP8) and MRP14) in human neutrophils. J Transl Med 3:36, 2005. doi:10.1186/1479-5876-3-36.
Skubitz KM, Haddad P. Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma, Cancer 104:361-366, 2005.
Iida J, Skubitz APN, McCarthy J, Skubitz KM. Protein kinase activity is associated with CD63 in melanoma cells. J Transl Med 3:42, 2005. doi:10.1186/1479-5876-3-42.
Skubitz KM, Zimmerman W, Kammerer R, Pambuccian S, Skubitz AP. Differential gene expression identifies subgroups of renal cell carcinoma. J Lab Clin Med. 2006; 147:250-67.
Skubitz AP, Pambuccian S, Argenta PA, Skubitz KM. Differential gene expression identifies subgroups of ovarian carcinoma. Transl Res 148:223-248, 2006.
Skubitz KM, Manivel JC. Giant cell tumor of the uterus: case report and response to chemotherapy. BMC Cancer 14;7:46, 2007.
Udhrain A, Skubitz KM, Northfelt DW. Pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi’s sarcoma. Int J Nanomedicine 2(3):345-352, 2007.
Skubitz KM, D’Adamo DR. Sarcoma. Mayo Clin. Proc., 82(11):1409-1432, 2007.
Verschraegen CF, Skubitz KM, Daud A, Kudelka A, Rabinowitz I, Allievi C, Eisenfeld A, Singer JW, Oldham FB. A phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors. Cancer Chemother. Pharmacol, 63:903-910, 2008.
Skubitz KM, Pambuccian S, Manivel JC, Skubitz AP. Identification of heterogeneity among soft tissue sarcomas by gene expression profiles from different tumors. J Transl Med. 2008; 6:23.
Tchagang AB, Tewfik AH, DeRycke MS, Skubitz KM, Skubitz AP. Early detection of ovarian cancer using group biomarkers. Mol Cancer Ther. 2008; 7:27-37.
Skubitz KM, Skubitz AP. Interdependency of CEACAM-1, -3, -6, and -8 induced human neutrophil adhesion to endothelial cells. J Transl Med. 2008; 6:78.
Skubitz KM, D’Adamo DR. Current treatment of sarcomas, in Neoplastic Hematology and Medical Oncology, Ed. Tefferi A, Rajkumar SV, Kantarjian H, Adjei A. Mayo Foundation for Medical Education and Research, Rochester, p. 397-420, 2008
Skubitz KM. Neutrophilic Leukocytes, in Wintrobe's Clinical Hematology, Twefth Edition, ed Lee GR, Foerster J, Greer J, Lukens J, Rodgers G, Paraskevas F, Williams and Wilkins, Baltimore, p.170-213, 2009.
Skubitz KM. Qualitative Disorders of Leukocytes, in Wintrobe's Clinical Hematology, Twelfth Edition, ed Lee GR, Foerster J, Greer J, Lukens J, Rodgers G, Paraskevas F. Williams and Wilkins, Baltimore, p. 1458-1564, 2009.
Thomas DM, Skubitz KM. Giant cell tumour of bone. Curr Opin Oncol. 2009 Jul;21(4):338-44. Review.
Skubitz KM, Manivel JC, Clohisy DR, Frolich JW. Response of imatinib-resistant extra-abdominal aggressive fibromatosis to sunitinib: case report and review of the literature on response to tyrosine kinase inhibitors. Cancer Chemother Pharmacol. 2009 Aug;64(3):635-40.
Cho JY, Katz DR, Skubitz KM, Chain BM. Conventional protein kinase C plays a critical role in negative regulation of CD98-induced homotypic aggregation. Tissue Antigens. 2010 Jan;75(1):19-29.
Thomas DM, Henshaw R, Skubitz KM, Chawla S, Staddon A, Blay JY, Roudier M, Smith J, Ye Z, Sohn W, Dansey R, Jun S. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol 11:275-280, 2010.
Skubitz KM, Skubitz AP. Two new synthetic peptides from the N-domain of CEACAM1 (CD66a) stimulate neutrophil adhesion to endothelial cells. Biopolymers. 96(1):25-31, 2010.
Benjamin R, Schoffski P, Hartmann JT, van Oosterom A, Bui BN, Duyster J, Schuetze S, Blay J, Reichardt P, Rosen L, Skubitz K, McCoy S, Sun YN, Stepan D, Baker L. Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors., Cancer Chemother Pharmacol Jul;68(1):69-77, 2011.
Skubitz KM, Francis P, Skubitz AP, Luo X, Nilbert M. Gene expression identifies heterogeneity of metastatic propensity in high-grade soft tissue sarcomas. Cancer. 2012; 118(17):4235-43.
Mitra AK, Kirstein MN, Khatri A, Skubitz KM, Dudek AZ, Greeno EW, Kratzke RA, Lamba JK. Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors. Pharmacogenomics. 2012; 13(9):1009-21.